Nephros Inc is a commercial-stage company that develops and sells high-performance water solutions to the medical and commercial markets... Show more
NEPH saw its Momentum Indicator move below the 0 level on February 03, 2026. This is an indication that the stock could be shifting in to a new downward move. Traders may want to consider selling the stock or exploring put options. Tickeron's A.I.dvisor looked at 95 similar instances where the indicator turned negative. In of the 95 cases, the stock moved further down in the following days. The odds of a decline are at .
The Moving Average Convergence Divergence Histogram (MACD) for NEPH turned negative on January 12, 2026. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 45 similar instances when the indicator turned negative. In of the 45 cases the stock turned lower in the days that followed. This puts the odds of success at .
NEPH moved below its 50-day moving average on January 08, 2026 date and that indicates a change from an upward trend to a downward trend.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where NEPH declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .
NEPH broke above its upper Bollinger Band on January 06, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Stochastic Oscillator shows that the ticker has stayed in the oversold zone for 3 days. The price of this ticker is presumed to bounce back soon, since the longer the ticker stays in the oversold zone, the more promptly an upward trend is expected.
Following a 3-day Advance, the price is estimated to grow further. Considering data from situations where NEPH advanced for three days, in of 208 cases, the price rose further within the following month. The odds of a continued upward trend are .
The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. NEPH’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating strong sales and a profitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (4.525) is normal, around the industry mean (11.448). P/E Ratio (30.429) is within average values for comparable stocks, (149.436). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.437). NEPH has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.017). P/S Ratio (2.577) is also within normal values, averaging (111.001).
The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. NEPH’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.
a medical device company, which engages in developing and selling liquid purification filters and an on-line mid dilution hemodiafiltration system
Industry PharmaceuticalsOther
A.I.dvisor indicates that over the last year, NEPH has been loosely correlated with SGHT. These tickers have moved in lockstep 34% of the time. This A.I.-generated data suggests there is some statistical probability that if NEPH jumps, then SGHT could also see price increases.
| Ticker / NAME | Correlation To NEPH | 1D Price Change % | ||
|---|---|---|---|---|
| NEPH | 100% | +6.03% | ||
| SGHT - NEPH | 34% Loosely correlated | +2.55% | ||
| IMDX - NEPH | 31% Poorly correlated | +5.21% | ||
| GH - NEPH | 28% Poorly correlated | +0.75% | ||
| AZTA - NEPH | 25% Poorly correlated | -3.47% | ||
| NEO - NEPH | 24% Poorly correlated | +2.07% | ||
More | ||||
| Ticker / NAME | Correlation To NEPH | 1D Price Change % |
|---|---|---|
| NEPH | 100% | +6.03% |
| Pharmaceuticals category (380 stocks) | 13% Poorly correlated | +27.23% |
| Pharmaceuticals: Other category (107 stocks) | 3% Poorly correlated | -0.87% |